IMR Press / FBL / Special Issues / 1465483999291252738

Progress in Nanoliposomes

Submission deadline: 31 August 2022
Special Issue Editors
Marcel R. Mozafari
Australasian nanoscience and nanotechnology initiative (ANNI), Glen Waverley, Victoria, Australia
Interests: Pharmaceutical nanotechnology; Nanobiotechnology; Theranostic delivery of bioactive compounds; Liposome; Nanoliposome; Tocosome; Mozafari method
Special Issue Information

Dear Colleagues,

Nanoliposome science and technology have shown great advances over the last few decades, with over 2500 articles published just in the last 12 months. Nanoliposomes are derived from an older technology, known as liposomes, that was initially produced at laboratory scale to study biological and biophysical properties of cell membranes. Gradually, the versatility of this supramolecular structure was explored as a gene, drug, food, cosmetic and vaccine delivery system. In order to explore their potential for human and animal use, the challenge became to manufacture nanoliposomes at industrial scale. Subsequently, more challenges emerged to make nanoliposome production feasible in pharmaceutical products. Problems associated with safety, particularly issues relating to the use of potentially toxic solvents and detergents, have been resolved by the advent of solvent-free and green technologies. These improvements in formulation and preparation protocols have resulted in several FDA-approved nanoliposomal products entering the market. This Special Issue focuses on recent advances in the manufacture of nanoliposomes, different methods for encapsulation of drugs, nutraceuticals, genes and vaccines, and advanced strategies to generate smart, targetable formulations.

This special issue will cover topics including:

· Green technologies for nanoliposome manufacture;

· Emerging protocols for drug and nutraceutical encapsulation;

· Recent nanoliposome applications in gene therapy;

· Targeting strategies in vitro and in vivo;

· Nanoliposome formulations for cancer diagnosis and therapy;

· Role of nanoliposomes in vaccine design and manufacture;

· Interaction of nanoliposomes with different macromolecules;

· Biophysics of nanoliposomes and associated technologies.


Prof. Dr. Marcel R. Mozafari

Guest Editor

Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Back to top